Blood-based biomarkers in mild behavioral impairment: an updated overview
Frontiers in Neurology,
Год журнала:
2025,
Номер
16
Опубликована: Фев. 6, 2025
Identifying
individuals
at-risk
for
dementia
is
one
of
the
critical
objectives
current
research
efforts,
highlighting
need
simple,
cost-effective,
and
minimally
invasive
biomarkers.
Mild
behavioral
impairment
(MBI),
characterized
by
emergence
persistent
neuropsychiatric
manifestations
in
older
adults,
has
attracted
increasing
attention
as
a
potential
early
indicator
cognitive
decline
dementia.
A
growing
number
studies
have
recently
begun
to
explore
relationship
between
MBI
several
blood-based
biomarkers
associated
with
Alzheimer's
disease
(AD)
pathology,
neurodegeneration,
well
systemic
metabolic
inflammatory
dysregulation.
In
this
context,
been
lower
plasma
Aβ42/Αβ40
ratio,
higher
phosphorylated
tau
at
threonine
181
(p-tau181),
increased
neurofilament
light
chain
(NfL)
levels,
disturbances
markers,
including
homocysteine,
insulin
ferritin,
suggesting
multifaceted
neurobiological
basis
syndrome.
These
findings
offer
insights
into
underlying
pathophysiology
MBI,
connection
symptoms
progression
AD.
narrative
review,
we
aim
summarize
critically
discuss
emerging
literature
evidence
linking
biomarkers,
hoping
shed
more
on
MBI's
pathophysiology,
its
AD-related
neurobiology,
practical
utility
predicting
impairment,
guiding
interventions
managing
risk
Язык: Английский
The prevalence of mild behavioral impairment in older adults with mild cognitive impairment: A systematic review and meta-analysis
Journal of Alzheimer s Disease,
Год журнала:
2025,
Номер
unknown
Опубликована: Март 28, 2025
Background
Mild
behavioral
impairment
is
a
neurobehavioral
symptom
characterized
by
the
onset
of
new
and
persistent
neuropsychiatric
syndrome.
Patients
with
co-occurring
mild
cognitive
have
relatively
highest
probability
developing
dementia
than
sick
or
alone.
Objective
This
study
aimed
to
determine
currently
available
best
estimate
prevalence
clarify
reasons
for
difference
in
estimates.
Methods
Data
were
retrieved
collected
from
five
electronic
databases.
Two
reviewers
independently
appraised
methodological
quality
included
studies.
Heterogeneity
was
assessed
using
I²
statistic
random
effects
models
employed.
Sources
heterogeneity
investigated
subgroup
analysis
meta-regression.
All
statistical
analyses
conducted
Stata.
Results
A
total
23
reports
involving
5397
participants
this
systematic
review.
The
pooled
effect
size
overall
52%
(95%CI
42-62%).
In
regression
analysis,
we
found
that
type,
area,
assessment
tools,
subject
gender
could
explain
part
source
heterogeneity.
Conclusions
results
review
suggest
combined
impairment;
there
close
relationship
between
two.
Future
studies
should
pay
more
attention
underlying
mechanism
two
provide
scientific
basis
early
discrimination
clinical
Alzheimer's
disease.
Язык: Английский
Unraveling the Potential Underlying Mechanisms of Mild Behavioral Impairment: Focusing on Amyloid and Tau Pathology
Cells,
Год журнала:
2024,
Номер
13(13), С. 1164 - 1164
Опубликована: Июль 8, 2024
The
emergence
of
sustained
neuropsychiatric
symptoms
(NPS)
among
non-demented
individuals
in
later
life,
defined
as
mild
behavioral
impairment
(MBI),
is
linked
to
a
higher
risk
cognitive
decline.
However,
the
underlying
pathophysiological
mechanisms
remain
largely
unexplored.
A
growing
body
evidence
has
shown
that
MBI
associated
with
alterations
structural
and
functional
neuroimaging
studies,
genetic
predisposition
clinical
diagnosis
Alzheimer’s
disease
(AD),
well
amyloid
tau
pathology
assessed
blood,
cerebrospinal
fluid,
positron-emission
tomography
(PET)
imaging
neuropathological
examination.
These
findings
shed
more
light
on
MBI-related
potential
neurobiological
mechanisms,
paving
way
for
development
targeted
pharmacological
approaches.
In
this
review,
we
aim
discuss
available
role
mechanisms.
Dysregulation
hypothalamic–pituitary–adrenal
(HPA)
axis,
disruption
neurotrophic
factors,
such
brain-derived
factor
(BDNF),
abnormal
neuroinflammatory
responses
including
kynurenine
pathway,
dysregulation
transforming
growth
beta
(TGF-β1),
epigenetic
micro-RNA
(miR)-451a
miR-455-3p,
synaptic
dysfunction,
imbalance
neurotransmitters
acetylcholine,
dopamine,
serotonin,
gamma-aminobutyric
acid
(GABA)
norepinephrine,
altered
locus
coeruleus
(LC)
integrity
are
some
connecting
pathology.
elucidation
neurobiology
would
facilitate
design
efficacy
relative
trials,
especially
towards
amyloid-
or
tau-related
pathways.
addition,
provide
insights
future
research
into
our
deeper
understanding
its
pathophysiology
MBI,
therapeutic
implications.
Язык: Английский
Human Leukocyte Antigen and microRNAs as Key Orchestrators of Mild Cognitive Impairment and Alzheimer’s Disease: A Systematic Review
International Journal of Molecular Sciences,
Год журнала:
2024,
Номер
25(15), С. 8544 - 8544
Опубликована: Авг. 5, 2024
The
expression
of
inflamma-miRs
and
human
leukocyte
antigen
(HLA)
haplotypes
could
indicate
mild
cognitive
impairment
(MCI)
Alzheimer’s
disease
(AD).
We
used
international
databases
to
conduct
a
systematic
review
studies
on
HLA
variants
meta-analysis
research
microRNAs
(miRNAs).
aimed
analyze
the
discriminative
value
miRNAs
in
MCI,
AD
controls
evaluate
protective
or
causative
effect
decline,
establish
role
as
biomarkers
for
early
detection
AD,
find
possible
link
between
HLA.
Statistical
analysis
was
conducted
using
Comprehensive
Meta-analysis
software,
version
2.2.050
(Biostat
Inc.,
Englewood,
NJ,
USA).
sizes
were
estimated
by
logarithm
base
2
fold
change.
revealed
that
some
variants,
such
HLA-B*4402,
HLA-A*33:01,
HLA-DPB1,
HLA-DR15,
HLA-DQB1*03:03,
HLA-DQB1*06:01,
HLA-DQB1*03:01,
SNPs
HLA-DRB1/DQB1,
HLA-DQA1,
predisposed
decline
before
occurrence
while
HLA-A1*01,
HLA-DRB1∗13:02,
HLA-DRB1*04:04,
HLA-DRB1*04:01
demonstrated
role.
identified
let-7
miR-15/16
AD.
association
these
two
miRNA
families
predispose
be
screening
prevention
MCI.
Язык: Английский
Pathophysiology of Alzheimer’s disease: an insight into the genetic factors, hypotheses, redox imbalance, and antioxidant intervention
Comparative Clinical Pathology,
Год журнала:
2024,
Номер
unknown
Опубликована: Сен. 13, 2024
Язык: Английский
Neobavaisoflavone Ameliorates Memory Deficits and Brain Damage in Aβ25‐35‐Induced Mice by Regulating SIRT1
CNS Neuroscience & Therapeutics,
Год журнала:
2024,
Номер
30(10)
Опубликована: Окт. 1, 2024
ABSTRACT
Background
Alzheimer's
disease
(AD)
is
a
common
chronic
neurodegenerative
in
older
people,
and
there
no
specific
treatment
that
can
stop
or
reverse
its
progression.
Neobavaisoflavone
(NBIF)
flavonoid
has
been
shown
to
have
neuroprotective
effects,
but
role
AD
not
revealed.
The
present
study
investigated
the
mechanism
of
NBIF
on
Aβ
25‐35
‐induced
brain
injury.
Methods
In
this
experiment,
mouse
model
was
established
by
injection
peptides
(200
μM,
icv),
Donepezil
(Don,
10
mg/kg/days),
NBIF‐L
(15
NBIF‐H
(30
mg/kg/days)
were
administered
orally
for
4
weeks.
Learning
memory,
hippocampal
pathological
changes,
markers,
apoptosis,
oxidative
stress,
inflammation,
immune
cells
measured
mice.
Network
pharmacology
combined
with
GEO
database
led
identification
SIRT1,
key
target
intervention
AD,
levels
p‐STAT3
FOXO1
measured.
addition,
antagonistic
activity
SIRT1
transfection
silencing
against
N9
N2a‐APP69
assess
whether
effects
caused
mediated
SIRT1.
Results
results
showed
ameliorated
learning
memory
neuronal
damage,
reduced
stress
neuroinflammation,
modulated
cells.
upregulates
reduces
expression
FOXO1.
Furthermore,
effectively
protective
effect
cells,
which
indicated
related
Conclusions
injury
inhibiting
may
be
through
signaling.
These
findings
provide
rationale
help
facilitate
development
clinical
therapeutic
agents
AD.
Язык: Английский
Apolipoprotein E (APOE) Isoforms, Neuropsychiatric Symptoms, and Sporadic Alzheimer’s Disease
Springer eBooks,
Год журнала:
2024,
Номер
unknown, С. 1 - 17
Опубликована: Янв. 1, 2024
Язык: Английский
Mild behavioral impairment in people with mild cognitive impairment: Are the two conditions related?
Journal of Alzheimer s Disease,
Год журнала:
2024,
Номер
unknown
Опубликована: Ноя. 8, 2024
Mild
cognitive
impairment
(MCI)
and
mild
behavioral
(MBI)
are
both
considered
potential
prodromal
stages
of
dementia,
especially
Alzheimer's
disease.
Previous
literature
has
lacked
specific
information
about
MBI
in
individuals
with
MCI
associations
several
aspects
both,
MCI.
Язык: Английский
Combined Experimental and Computational Investigations of 4‐Amino‐2‐Chloro‐6,7‐Dimethoxyquinazoline as Potential Anti‐Alzheimer Agent
Karthikeyan Asokan,
Karthik Nallasamy,
S. Sivaraman
и другие.
International Journal of Quantum Chemistry,
Год журнала:
2024,
Номер
124(24)
Опубликована: Дек. 10, 2024
ABSTRACT
Alzheimer's
disease
(AD)
is
a
neurodegenerative
condition
that
leads
to
the
deterioration
of
brain
cells,
resulting
in
memory
loss,
thinking,
and
executive
skills.
In
this
work,
4‐amino‐2‐chloro‐6,7‐dimethoxyquinazoline
(ACDQ)
has
been
studied
using
6–311++G(d,p)
B3LYP
functional
density
theory
(DFT)
approach
utilizing
basis
set.
Geometry
optimization
fundamental
vibrational
frequencies
are
calculated
above
method.
The
spectroscopic
investigations
such
as
FT‐IR,
FT‐Raman,
UV–Vis
spectra
performed
on
selected
compound.
time‐dependent
DFT
calculations
gas
water
phases
determine
electronic
properties
energy
gap
same
Charge
distributions
have
used
illustrate
between
highest
occupied
lowest
unoccupied
molecular
orbitals.
Mulliken
population
analysis
atomic
charges
ACDQ.
From
natural
bond
orbital
analysis,
it
observed
there
significant
electron
delocalization
ACDQ
due
presence
intramolecular
interactions.
To
evaluate
ACDQ's
anti‐Alzheimer
potential,
docking
simulation
assess
its
structural
stability
biological
activity
against
proteins
associated
with
disease.
Our
study
revealed
that,
strong
interaction
4EY7
protein
binding
−8.1
kcal
mol
−1
.
Additionally,
metrics
root
mean
square
deviation
(RMSD),
fluctuation
(RMSF),
radius
gyration
considered
(
R
g
)
were
computed
dynamics
simulations
protein–ligand
interaction.
Studies
ADMET
prediction
also
carried
out.
findings
current
support
potential
an
effective
lead
therapeutic
for
Язык: Английский